Wednesday, 20 June 2012

Pryflex


Generic Name: chondroitin and glucosamine (kon DROI tin and gloo KOE sa meen)

Brand Names: Cosamin DS, Osteo Bi-Flex, Osteo Bi-Flex Double Strength, Osteo Bi-Flex Triple Strength, Pryflex, Relamine, Schiff Move Free, Schiff Move Free Caplets


What is Pryflex (chondroitin and glucosamine)?

Chondroitin is a naturally occurring substance formed of sugar chains. Chondroitin is believed to help the body maintain fluid and flexibility in the joints.


Glucosamine is sugar protein that is believed to help develop and renew cartilage (the hard connective tissue mainly located on bones near joints in the body), and keep it lubricated for better joint movement and flexibility.


The combination of chondroitin and glucosamine is widely used to aid in maintaining healthy joints. It is also used as a nutritional supplement in people with osteoarthritis or other inflammatory joint disorders.


Not all uses for chondroitin and glucosamine have been approved by the FDA. Chondroitin and glucosamine should not be substituted for medications prescribed for you by your doctor.

Chondroitin and glucosamine is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.


Chondroitin and glucosamine may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Pryflex (chondroitin and glucosamine)?


Not all uses for chondroitin and glucosamine have been approved by the FDA. Chondroitin and glucosamine should not be substituted for medications prescribed for you by your doctor.

Chondroitin and glucosamine is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.


Before using chondroitin and glucosamine, talk to your doctor, pharmacist, herbalist, or other healthcare provider. You may not be able to use chondroitin and glucosamine if you have diabetes, a bleeding or blood clotting disorder such as hemophilia, if you have allergies to certain drugs, if you are overweight, or if you are on a low-salt diet.


Use chondroitin and glucosamine as directed on the label, or as your healthcare provider has prescribed. Do not use this product in larger amounts or for longer than recommended.


Do not take chondroitin and glucosamine without the advice of a healthcare provider if you are using insulin, or a blood thinner such as warfarin (Coumadin). Avoid taking chitosan (usually marketed as a weight-loss product) while you are taking chondroitin and glucosamine. Chitosan can make it harder for your body to absorb chondroitin.

What should I tell my healthcare provider before taking Pryflex (chondroitin and glucosamine)?


Before using chondroitin and glucosamine, talk to your doctor, pharmacist, herbalist, or other healthcare provider. You may not be able to use chondroitin and glucosamine if you have:



  • diabetes;




  • a bleeding or blood clotting disorder such as hemophilia;




  • if you have allergies to certain drugs;




  • if you are overweight; or




  • if you are on a low-salt diet.




Chondroitin and glucosamine may or may not be harmful to an unborn baby. Do not use this product without talking to a healthcare provider if you are pregnant or plan to become pregnant during treatment. It is not known whether chondroitin and glucosamine can pass into breast milk or if it could harm a nursing baby. Ask your healthcare provider before using chondroitin and glucosamine if you are breast-feeding a baby.

How should I take Pryflex (chondroitin and glucosamine)?


When considering the use of herbal supplements, seek the advice of your doctor. You may also consider consulting a practitioner who is trained in the use of herbal/health supplements.


If you choose to take chondroitin and glucosamine, use it as directed on the package or as directed by your doctor, pharmacist, or other healthcare provider. Do not use more of chondroitin and glucosamine than is recommended on the label.


Chondroitin and glucosamine is usually taken 1 or 2 times per day. You may need to take the medication 3 times per day for the first couple of months of treatment. Follow your doctor's instructions.


Glucosamine may increase the glucose (sugar) levels in your blood. If you have diabetes, you may need to check your blood sugar more often while taking this medication. You may also need to adjust your insulin dosage. Do not change your dose or medication schedule without advice from your doctor.


Chondroitin and glucosamine may be only part of a complete program of treatment that also includes diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely.


Store this medication at room temperature away from moisture, heat, and light.

What happens if I miss a dose?


Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Pryflex (chondroitin and glucosamine)?


Avoid taking chitosan (usually marketed as a weight-loss product) while you are taking chondroitin and glucosamine. Chitosan can make it harder for your body to absorb chondroitin.

Pryflex (chondroitin and glucosamine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:



  • mild nausea, upset stomach;




  • heartburn; or




  • diarrhea.



This is not a complete list of side effects and others may occur. Tell your doctor, pharmacist, herbalist, or other healthcare provider about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Pryflex (chondroitin and glucosamine)?


Do not take chondroitin and glucosamine without the advice of a healthcare provider if you are using any of the following medications:

  • insulin; or




  • a blood thinner such as warfarin (Coumadin).



This list is not complete and other drugs may interact with chondroitin and glucosamine. Tell your healthcare provider about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Pryflex resources


  • Pryflex Use in Pregnancy & Breastfeeding
  • Pryflex Drug Interactions
  • Pryflex Support Group
  • 0 Reviews for Pryflex - Add your own review/rating


  • Osteo Bi-Flex Triple Strength caplets

  • Relamine MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Pryflex with other medications


  • Dietary Supplementation
  • Osteoarthritis


Where can I get more information?


  • Consult with a licensed healthcare professional before using any herbal/health supplement. Whether you are treated by a medical doctor or a practitioner trained in the use of natural medicines/supplements, make sure all your healthcare providers know about all of your medical conditions and treatments.


Tuesday, 19 June 2012

Fluarix



influenza virus vaccine

Dosage Form: injection
FULL PRESCRIBING INFORMATION

Indications and Usage for Fluarix


  Fluarix® is indicated for active immunization for the prevention of disease caused by influenza virus subtypes A and type B contained in the vaccine. Fluarix is approved for use in persons 3 years of age and older.



Fluarix Dosage and Administration



Preparation for Administration


Shake well before administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.



Recommended Dose and Schedule


Fluarix should be administered as an intramuscular injection preferably in the region of the deltoid muscle of the upper arm.


 Children: Children 3 years to <9 years of age previously unvaccinated or vaccinated for the first time last season with only one dose receive two 0.5 mL doses; each 0.5 mL dose is administered at least 4 weeks apart.


  Children 3 years to <9 years of age who have been previously vaccinated with 2 doses of any influenza vaccine receive only one 0.5 mL dose.


  Children 9 years of age and older receive only one 0.5 mL dose.


Adults: Administer as a single 0.5 mL dose.


  Do not administer this product intravenously, intradermally, or subcutaneously.


Do not inject in the gluteal area or areas where there may be a major nerve trunk.



Dosage Forms and Strengths


Fluarix is a suspension available in 0.5-mL single-dose prefilled TIP-LOK® syringes.



Contraindications


Do not administer Fluarix to anyone with known systemic hypersensitivity reactions to egg proteins (a vaccine component) or a life-threatening reaction to previous administration of any influenza vaccine [see Description (11)].



Warnings and Precautions



Guillain-Barré Syndrome


  If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give Fluarix should be based on careful consideration of the potential benefits and risks.



Latex


The tip caps of the prefilled syringes may contain natural rubber latex which may cause allergic reactions in latex sensitive individuals [see Description (11)].



Altered Immunocompetence


If Fluarix is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons.



Preventing and Managing Allergic Vaccine Reactions


Prior to administration, the healthcare provider should review the patient's immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of Fluarix.



Limitations of Vaccine Effectiveness


Vaccination with Fluarix may not protect all susceptible individuals.



Persons at Risk of Bleeding


  As with other intramuscular injections, Fluarix should be given with caution in individuals with bleeding disorders such as hemophilia or on anticoagulant therapy, to avoid the risk of hematoma following the injection.



Adverse Reactions



Clinical Trials Experience


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine, and may not reflect the rates observed in practice. There is the possibility that broad use of Fluarix could reveal adverse reactions not observed in clinical trials.


Adults: In adults, the most common local adverse reactions and general adverse events observed with Fluarix were pain and redness at the injection site, muscle aches, fatigue, and headache.


Fluarix has been administered to 10,317 adults 18 to 64 years of age and 606 subjects ≥65 years of age in 4 clinical trials.


One of the 4 clinical trials was a randomized, double-blind, placebo-controlled study that evaluated a total of 952 subjects: Fluarix (N = 760) and placebo (N = 192). The population was 18 to 64 years of age (mean 39.1), 54% were female and 80% were white. Solicited events were collected for 4 days (day of vaccination and the next 3 days) (Table 1). Unsolicited events that occurred within 21 days of vaccination (day 0-20) were recorded using diary cards supplemented by spontaneous reports and a medical history as reported by subjects.


Table 1. Percentage of Subjects With Solicited Local Adverse Reactions or General Adverse Events Within 4 Daysa of Vaccination (Total Vaccinated Cohort)




































Fluarix


N = 760


%



Placebo


N = 192


%


Local Adverse Reactions
Pain5512
Redness1810
Swelling96
General Adverse Events
Muscle aches2312
Fatigue2018
Headache1921
Arthralgia66
Shivering33
Fever (≥100.4°F)22

Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available.


a 4 days included day of vaccination and the subsequent 3 days.


Unsolicited adverse events that occurred in ≥1% of recipients of Fluarix and at a rate greater than placebo included upper respiratory tract infection (3.9% versus 2.6%), nasopharyngitis (2.5% versus 1.6%), nasal congestion (2.2% versus 2.1%), diarrhea (1.6% versus 0%), influenza-like illness (1.6% versus 0.5%), vomiting (1.4% versus 0%), and dysmenorrhea (1.3% versus 1.0%).


A randomized, single-blind, active-controlled US study evaluated subjects randomized to receive Fluarix (N = 917) or FLUZONE (N = 910), a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA) stratified by age: 18 to 64 years and ≥65 years of age. In the overall population, 59% of subjects were female and 91% were white. Solicited events were collected using diary cards for 4 days (day of vaccination and the next 3 days) (Table 2). Unsolicited events that occurred within 21 days of vaccination (day 0-20) were recorded using diary cards.


Table 2. Percentage of Subjects With Solicited Local Adverse Reactions or General Adverse Events Within 4 Daysa of Vaccination With Fluarix or Comparator Influenza Vaccine by Age Group (Total Vaccinated Cohort)


























































18-64 Years of Age≥65 Years of Age

Fluarix


N = 315


%

Comparator Influenza Vaccine


N = 314


%

Fluarix


N = 601-602


%

Comparator Influenza Vaccine


N = 596


%
Local Adverse Reactions
Pain48531918
Redness13161113
Swelling91169
General Adverse Events
Fatigue2118910
Headache202188
Muscle aches161377
Arthralgia9965
Shivering3522
Fever (≥99.5°F)3121

Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available.


a 4 days included day of vaccination and the subsequent 3 days.


Unsolicited adverse events that occurred in ≥1% of all recipients of Fluarix or the comparator influenza vaccine in the 21-day post-vaccination period included headache (2.8% versus 2.3%), back pain (1.5% versus 0.4%), pain in extremity (1.2% versus 0.7%), pharyngolaryngeal pain (1.2% versus 0.9%), cough (1.1% versus 0.9%), fatigue (1.1% versus 0.7%), nasopharyngitis (1.0% versus 1.3%), nausea (0.4% versus 1.0%), arthralgia (0.3% versus 1.0%), and injection site pruritus (0.2% versus 1.0%).


A double-blind, placebo-controlled study in subjects 18 to 64 years of age randomized (2:1) to receive Fluarix (N = 5,103) or placebo (N = 2,549) was conducted to evaluate the efficacy of Fluarix. In the total population, 60% were female and 99.9% were white. In a subset (Fluarix [N = 305] and placebo [N = 155]), unsolicited events that occurred within 21 days of vaccination (day 0-20) were recorded on diary cards. The percentage of subjects reporting at least one unsolicited event was similar among the groups (24.3% for Fluarix and 22.6% for placebo). Unsolicited adverse events that occurred in ≥1% of recipients of Fluarix and at a rate greater than placebo included injection site pain (5.2% versus 1.3%), dysmenorrhea (1.3% versus 0.6%), and migraine (1.0% versus 0.0%).


Incidence of Adverse Events Reported in ≥1% of Subjects in Non-US Clinical Trials: The following additional adverse events have been observed in adults in non-US clinical trials with Fluarix. No adverse events were observed at an incidence of >10%.


General Disorders and Administration Site Conditions: Injection site ecchymosis, injection site induration, malaise.


Infections and Infestations: Rhinitis.


Musculoskeletal and Connective Tissue Disorders: Musculoskeletal pain, neck pain.


Skin and Subcutaneous Tissue Disorders: Sweating.


Serious Adverse Events: In the 4 clinical trials in adults (N = 10,923), there was a single case of anaphylaxis reported with Fluarix (<0.01%).


Children: In children 5 years to <18 years of age, the most common (≥10%) local and general adverse events were similar to those in adults but also included swelling at the injection site. In children 3 years to <5 years of age, the most common (≥10%) local and general adverse events included pain, redness, and swelling at the injection site, irritability, loss of appetite, and drowsiness.


A single-blind, active-controlled US study evaluated subjects 6 months to <18 years of age who received Fluarix (N = 2,081) or FLUZONE (N = 1,173), a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA) (Study 005). Children 6 months to <9 years of age with no history of influenza vaccination received 2 doses approximately 28 days apart. Children 6 months to <9 years of age with a history of influenza vaccination and children 9 years of age and older received 1 dose. Children 6 months to <3 years of age received 0.25 mL of Fluarix or comparator influenza vaccine, and children 3 years of age and older received 0.5 mL of Fluarix or comparator influenza vaccine.


Study subjects were 6 months to <18 years of age and 49% were female; 68% were white, 18% were black, 3% were Asian, and 11% were of other racial/ethnic groups.


Solicited local and general adverse events were collected using diary cards for 4 days (day of vaccination and the next 3 days). Unsolicited adverse events that occurred within 28 days of vaccination (day 0-27) after the first vaccination in all subjects and 21 days (day 0-20) after the second vaccination in unprimed subjects were recorded using diary cards.


The frequencies of solicited adverse events for children 3 years to <5 years of age and for children 5 years to <18 years of age were similar for Fluarix and the comparator vaccine (Table 3).


Table 3. Percentage of Subjects With Solicited Local Adverse Reactions or General Adverse Events Within 4 Daysa of First Vaccination With Fluarix or Comparator Influenza Vaccine by Age Group in Children 3 Years to <18 Years of Age









































































Age Group: 3 Years to <5 YearsAge Group: 5 Years to <18 Years

Fluarix


N = 350


%

Comparator Influenza Vaccine


N = 341


%

Fluarix


N = 1,348


%

Comparator Influenza Vaccine


N = 451


%
Local Adverse Reactions
Pain35385656
Redness23201816
Swelling14131413
General Adverse Events
Irritability2122––
Loss of appetite1315––
Drowsiness1320––
Fever7843
Muscle aches––2929
Fatigue––2019
Headache––1516
Arthralgia––66
Shivering––34

a 4 days included day of vaccination and the subsequent 3 days.


In children who received a second dose of Fluarix or the comparator vaccine, the incidences of adverse events following the second dose were similar to those observed after the first dose.


Unsolicited adverse events that occurred in ≥1% of recipients of Fluarix 6 months to <18 years of age included upper respiratory tract infection (5.5%), pyrexia (4.8%), cough (4.7%), vomiting (3.2%), headache (2.8%), rhinorrhea (2.7%), diarrhea (2.5%), pharyngolaryngeal pain (2.4%), nasopharyngitis (2.3%), otitis media (2.0%), nasal congestion (1.8%), upper abdominal pain (1.4%), and upper respiratory tract congestion (1.0%). The incidences of these events were similar in recipients of the comparator vaccine.



Postmarketing Experience


Worldwide voluntary reports of adverse events received for Fluarix since market introduction of this vaccine are listed below. This list includes serious events or events which have causal connection to Fluarix. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.


Blood and Lymphatic System Disorders: Lymphadenopathy.


Cardiac Disorders: Tachycardia.


Ear and Labyrinth Disorders: Vertigo.


Eye Disorders: Conjunctivitis, eye irritation, eye pain, eye redness, eye swelling, eyelid swelling.


Gastrointestinal Disorders: Abdominal pain or discomfort, nausea, swelling of the mouth, throat, and/or tongue.


General Disorders and Administration Site Conditions: Asthenia, chest pain, chills, feeling hot, injection site mass, injection site reaction, injection site warmth, body aches.


Immune System Disorders: Anaphylactic reaction including shock, anaphylactoid reaction, hypersensitivity, serum sickness.


Infections and Infestations: Injection site abscess, injection site cellulitis, pharyngitis, rhinitis, tonsillitis.


Musculoskeletal and Connective Tissue Disorders: Pain in extremity.


Nervous System Disorders: Convulsion, dizziness, encephalomyelitis, facial palsy, facial paresis, Guillain-Barré syndrome, hypoesthesia, myelitis, neuritis, neuropathy, paresthesia.


Respiratory, Thoracic, and Mediastinal Disorders: Asthma, bronchospasm, cough, dyspnea, respiratory distress, stridor.


Skin and Subcutaneous Tissue Disorders: Angioedema, erythema, erythema multiforme, facial swelling, pruritus, rash, Stevens-Johnson syndrome, urticaria.


Vascular Disorders: Henoch-Schönlein purpura, vasculitis.



Adverse Events Associated With Influenza Vaccines


Immediate and presumably allergic reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) rarely occur after influenza vaccination. These reactions probably result from hypersensitivity to certain vaccine components, such as residual egg protein. Although Fluarix contains only a limited quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe egg allergy [see Contraindications (4)].


The 1976 swine influenza vaccine was associated with an increased frequency of Guillain-Barré syndrome (GBS). Evidence for a causal relation of GBS with subsequent vaccines prepared from other influenza viruses is unclear. If influenza vaccine does pose a risk, it is probably slightly more than 1 additional case/1 million persons vaccinated.


Neurological disorders temporally associated with influenza vaccination such as encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy have been reported.


Microscopic polyangitis (vasculitis) has been reported temporally associated with influenza vaccination.



Drug Interactions



Concomitant Vaccine Administration


Fluarix should not be mixed with any other vaccine in the same syringe or vial.


There are insufficient data to assess the concurrent administration of Fluarix with other vaccines.



Immunosuppressive Therapies


Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to Fluarix.



USE IN SPECIFIC POPULATIONS



Pregnancy


  Pregnancy Category B


A reproductive and developmental toxicity study has been performed in female rats at a dose approximately 56 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to Fluarix. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Fluarix should be given to a pregnant woman only if clearly needed.


In a reproductive and developmental toxicity study, the effect of Fluarix on embryo-fetal and pre-weaning development was evaluated in pregnant rats. Animals were administered Fluarix by intramuscular injection once prior to gestation, and during the period of organogenesis (gestation days 6, 8, 11, and 15), 0.1 mL/rat/occasion (approximately 56-fold excess relative to the projected human dose on a body weight basis). No adverse effects on mating, female fertility, pregnancy, parturition, lactation parameters, and embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis.



Nursing Mothers


It is not known whether Fluarix is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fluarix is administered to a nursing woman.



Pediatric Use


The immune response of Fluarix has been evaluated in children 6 months to <5 years of age. In a randomized, controlled study, serum hemagglutination-inhibition (HI) antibody titers were lower in children 6 months to <3 years of age compared to a US-licensed vaccine. Immune responses in children 3 years to <5 years of age receiving Fluarix or a US-licensed vaccine have been evaluated [see Clinical Studies (14.2)]. Safety has been evaluated in children 6 months to <18 years of age. The frequencies of solicited adverse events for children 3 years to <5 years of age and for children 5 years to <18 years of age were similar for Fluarix and the comparator vaccine [see Adverse Reactions (6.1)].



Geriatric Use


A randomized, single-blind, active-controlled study evaluated immunological non-inferiority in a cohort of subjects ≥65 years of age who received Fluarix (N = 606) or another US-licensed trivalent, inactivated influenza virus vaccine (N = 604) (Sanofi Pasteur SA). In subjects receiving Fluarix or the comparator vaccine, geometric mean antibody titers post-vaccination were lower in geriatric subjects than in younger subjects (18 to 64 years of age). Fluarix was non-inferior to the comparator vaccine for each of the 3 influenza strains based on mean antibody titers and seroconversion rates. [See Clinical Studies (14.2).] Solicited local and general adverse events were similar for Fluarix and the comparator vaccine among geriatric subjects (Table 2). For both vaccines, the frequency of solicited events in subjects ≥65 years of age was lower than in younger subjects (Table 2). [See Adverse Reactions (6.1).]



Fluarix Description


Fluarix, Influenza Virus Vaccine, for intramuscular injection, is a sterile colorless to slightly opalescent suspension. Fluarix is a vaccine prepared from influenza viruses propagated in embryonated chicken eggs. Each of the influenza viruses is produced and purified separately. After harvesting the virus-containing fluids, each influenza virus is concentrated and purified by zonal centrifugation using a linear sucrose density gradient solution containing detergent to disrupt the viruses. Following dilution, the vaccine is further purified by diafiltration. Each influenza virus solution is inactivated by the consecutive effects of sodium deoxycholate and formaldehyde leading to the production of a “split virus.” Each split inactivated virus is then suspended in sodium phosphate-buffered isotonic sodium chloride solution. The vaccine is formulated from the 3 split inactivated virus solutions.


Fluarix has been standardized according to USPHS requirements for the 2010-2011 influenza season and is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5-mL dose, in the recommended ratio of 15 mcg HA of each of the following 3 strains: A/California/7/2009 NYMC X-181 (H1N1), A/Victoria/210/2009 NYMC X-187 (H3N2) (an A/Perth/16/2009-like virus),and B/Brisbane/60/2008.


Fluarix is formulated without preservatives. Fluarix does not contain thimerosal. Each 0.5-mL dose also contains octoxynol-10 (TRITON® X-100) ≤0.085 mg, α-tocopheryl hydrogen succinate ≤0.1 mg, and polysorbate 80 (Tween 80) ≤0.415 mg. Each dose may also contain residual amounts of hydrocortisone ≤0.0016 mcg, gentamicin sulfate ≤0.15 mcg, ovalbumin ≤0.05 mcg, formaldehyde ≤5 mcg, and sodium deoxycholate ≤50 mcg from the manufacturing process.


The tip caps of the prefilled syringes may contain natural rubber latex. The rubber plungers do not contain latex.



Fluarix - Clinical Pharmacology



Mechanism of Action


Influenza illness and its complications follow infection with influenza viruses. Global surveillance of influenza identifies yearly antigenic variants. For example, since 1977, antigenic variants of influenza A (H1N1 and H3N2) viruses and influenza B viruses have been in global circulation. Specific levels of hemagglutination-inhibition (HI) antibody titer post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness but the HI antibody titers have been used as a measure of vaccine activity. In some human challenge studies, HI antibody titers of ≥1:40 have been associated with protection from influenza illness in up to 50% of subjects.1,2 Antibody against one influenza virus type or subtype confers little or no protection against another virus. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virological basis for seasonal epidemics and the reason for the usual incorporation of one or more new strains in each year’s influenza vaccine. Therefore, inactivated influenza vaccines are standardized to contain the hemagglutinins of strains (i.e., typically 2 type A and 1 type B), representing the influenza viruses likely to circulate in the United States in the upcoming winter.


Annual revaccination with the current vaccine is recommended because immunity declines during the year after vaccination, and because circulating strains of influenza virus change from year to year.3



Nonclinical Toxicology



Carcinogenesis, Mutagenesis, Impairment of Fertility


Fluarix has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.



Clinical Studies



Efficacy Against Culture-Confirmed Influenza


The efficacy of Fluarix was evaluated in a randomized, double-blind, placebo-controlled study conducted in 2 European countries during the 2006-2007 influenza season. Efficacy of Fluarix, containing A/New Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 influenza strains, was defined as the prevention of culture-confirmed influenza A and/or B cases, for vaccine antigenically matched strains, compared with placebo. Healthy subjects 18 to 64 years of age (mean 39.9 years) were randomized (2:1) to receive Fluarix (N = 5,103) or placebo (N = 2,549) and monitored for influenza-like illnesses (ILI) starting 2 weeks post vaccination and lasting for approximately 7 months. In the overall population, 60% of subjects were female and 99.9% were white. Culture-confirmed influenza was assessed by active and passive surveillance of ILI. Influenza-like illness was defined as at least one general symptom (fever ≥100°F and/or myalgia) and at least one respiratory symptom (cough and/or sore throat). After an episode of ILI, nose and throat swab samples were collected for analysis; attack rates and vaccine efficacy were calculated (Table 4).


Table 4. Attack Rates and Vaccine Efficacy Against Culture-Confirmed Influenza A and/or B in Adults 18 to 64 Years of Age (Total Vaccinated Cohort)











































Attack Rates (n/N)Vaccine Efficacy
Nn%%LLUL
Antigenically Matched Strainsa
Fluarix5,103491.066.9b51.977.4
Placebo2,549742.9–––
All Culture-Confirmed Influenza (Matched, Unmatched, and Untyped)c
Fluarix5,103631.261.6b46.072.8
Placebo2,549823.2–––

aThere were no vaccine matched culture-confirmed cases of A/New Caledonia/20/1999 (H1N1) or B/Malaysia/2506/2004 influenza strains with Fluarix or placebo.


b Vaccine efficacy for Fluarix exceeded a pre-defined threshold of 35% for the lower limit of the 2-sided 95% CI.


c Of the 22 additional cases, 18 were unmatched and 4 were untyped; 15 of the 22 cases were A (H3N2) (11 cases with Fluarix and 4 cases with placebo).


In a post-hoc, exploratory analysis by age, vaccine efficacy (against culture-confirmed influenza A and/or B cases, for vaccine antigenically matched strains) in subjects 18 to 49 years of age was 73.4% (95% CI: 59.3, 82.8) [number of influenza cases: Fluarix (n = 35/3,602) and placebo (n = 66/1,810)]. In subjects 50 to 64 years of age, vaccine efficacy was 13.8% (95% CI: -137.0, 66.3) [number of influenza cases: Fluarix (n = 14/1,501) and placebo (n = 8/739)]. As the study lacked statistical power to evaluate efficacy within age subgroups, the clinical significance of these results is unknown.



Immunological Evaluation


Adults: In a randomized, double-blind, placebo-controlled study conducted in healthy subjects 18 to 64 years of age (mean 39.1 years) in the United States, the immune responses to each of the antigens contained in Fluarix were evaluated in sera obtained 21 days after administration of Fluarix (N = 745) and were compared to those following administration of a placebo vaccine (N = 190). In the overall population, 54% of subjects were female and 80% were white. For each of the influenza antigens, the percentage of subjects who achieved seroconversion, defined as at least a 4-fold increase in serum hemagglutination-inhibition (HI) titer over baseline to ≥1:40 following vaccination, and the percentage of subjects who achieved HI titers of ≥1:40 are presented in Table 5. The lower limit of the 2-sided 95% CI for the percentage of subjects who achieved seroconversion or an HI titer of ≥1:40 exceeded the pre-defined lower limits of 40% and 70%, respectively.


Table 5. Rates With HI Titers ≥1:40 and Rates of Seroconversion to Each Antigen Following Fluarix or Placebo (21 Days After Vaccination) in Adults 18 to 64 Years of Age (ATP Cohort)







































Fluarixa


N = 745


% (95% CI)

Placebo


N = 190


% (95% CI)
% With HI Titers ≥1:40Pre-vaccinationPost-vaccinationPre-vaccinationPost-vaccination
A/New Caledonia/20/99 (H1N1)

54.8


(51.1, 58.4)

96.6


(95.1, 97.8)

52.1


(44.8, 59.4)

51.1


(43.7, 58.4)
A/Wyoming/3/2003 (H3N2)

68.7


(65.3, 72)

99.1


(98.1, 99.6)

65.3


(58, 72)

65.3


(58, 72)
B/Jiangsu/10/2003

49.5


(45.9, 53.2)

98.8


(97.7, 99.4)

48.9


(41.6, 56.3)

51.1


(43.7, 58.4)
SeroconversionbPost-vaccinationPost-vaccination
A/New Caledonia/20/99 (H1N1)59.6 (56, 63.1)0 (0, 1.9)
A/Wyoming/3/2003 (H3N2)61.9 (58.3, 65.4)1.1 (0.1, 3.8)
B/Jiangsu/10/200377.6 (74.4, 80.5)1.1 (0.1, 3.8)

HI = hemagglutination-inhibition; ATP = according-to-protocol; CI = Confidence Interval.


ATP cohort for immunogenicity included subjects for whom assay results were available after vaccination for at least one study vaccine antigen.


a Results obtained following vaccination with Fluarix manufactured for the 2004-2005 season.


bSeroconversion defined as at least a 4-fold increase in serum titers of HI antibodies to ≥1:40.


Non-Inferiority Study: In a randomized, single-blind, active-controlled US study, immunological non-inferiority of Fluarix (N = 923) was compared with FLUZONE (N = 922), a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA). Subjects 18 to 64 years and ≥65 years of age were evaluated for immune responses to each of the vaccine antigens 21 days following vaccination [see Use in Specific Populations (8.5)]. In the overall population, 59% of subjects were female and 91% were white. The co-primary immunogenicity endpoints were geometric mean titers (GMTs) of serum HI antibodies and the percentage of subjects who achieved seroconversion, defined as at least a 4-fold increase in serum HI titer over baseline to ≥1:40, following vaccination. The primary immunogenicity analyses were performed on the According-to-Protocol (ATP) cohort which included all eligible and evaluable subjects with results of at least one serological assay. For each of the influenza antigens, the GMTs and the percentage of subjects who achieved seroconversion are presented in Table 6. Fluarix was non-inferior to the comparator influenza vaccine based on antibody GMTs (upper limit of the 2-sided 95% CI for the GMT ratio [comparator influenza vaccine/Fluarix] ≤1.5) and seroconversion rates (upper limit of the 2-sided 95% CI on difference of the comparator influenza vaccine minus Fluarix ≤10%).


Table 6. Immune Responses 21 Days After Vaccination With Fluarix Compared With Comparator Influenza Vaccine in Adults ≥18 Years of Age (ATP Cohort)










Fluarix


N = 858-866

Comparator


Influenza Vaccine


N = 846-854
GMT (95% CI)Pre-vaccinationPost-vaccinationPre-

Monday, 18 June 2012

Apomorphine Hydrochloride


Class: Nonergot-derivative Dopamine Receptor Agonists
VA Class: CN500
Chemical Name: 5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol hydrochloride
Molecular Formula: C17H17NO2•HCl•½H2O
CAS Number: 41372-20-7
Brands: Apokyn

Introduction

Nonergot-derivative dopamine receptor agonist.1 4


Uses for Apomorphine Hydrochloride


Hypomobility Episodes Associated with Parkinson’s Disease


Acute, intermittent treatment of episodes of hypomobility (i.e., “off” episodes, including end-of-dose “wearing off” and unpredictable “on-off” episodes) associated with advanced Parkinson’s disease (designated an orphan drug by FDA for this use).1 2 3 4 6 5 8 9 11 12 13 14


Used as an adjunct to other antiparkinsonian agents (e.g., levodopa, oral dopamine receptor agonists).1 2 5 8 11


Acute Poisoning


Formerly used to induce vomiting in the early management of acute oral drug overdose and in certain cases of oral poisoning (dose: 5–6 mg sub-Q)†.15


Apomorphine Hydrochloride Dosage and Administration


General



  • Administer an antiemetic (i.e., trimethobenzamide hydrochloride 300 mg orally 3 times daily) beginning 3 days prior to initiation of apomorphine; continue for the first 2 months of therapy or until tolerance to nausea and vomiting develops.1 11




  • Avoid certain other antiemetic agents (i.e., selective 5-HT3 receptor antagonists, dopamine-receptor antagonists [metoclopramide, phenothiazines]).1 4 (See Contraindications under Cautions and Specific Drugs under Interactions.)



Administration


Sub-Q Administration


Administer by sub-Q injection using the dosing pen on an as-needed basis to reverse “off” episodes.1


Administer sub-Q injections in the abdomen, thigh, or upper arm; rotate injection sites.1


Test dose: Administer all test doses in a medical setting where BP can be closely monitored.1 Measure supine and standing BP prior to and 20, 40, and 60 minutes after each test dose.1


Test dose: Determine dose when patient is experiencing an “off” episode.1 Induction of an “off” state can be facilitated by withholding the patient’s antiparkinsonian agents overnight.1


Do not administer IV; possibility of serious adverse effects (e.g., thrombosis, pulmonary embolism).1


Dosage


Available as apomorphine hydrochloride; dosage expressed in terms of the salt.1


Provide dosing instructions for the patient or their caregiver in mL; dose on the dosing pen device is expressed in terms of mL.1


Titrate dose according to patient's response and tolerance.1


Adults


Hypomobility Episodes Associated with Parkinson’s Disease

Sub–Q

Initial test dose is 0.2 mL (2 mg).1 If the 0.2-mL (2-mg) dose is effective and tolerated, this dose may be used on an as-needed, outpatient basis.1 If necessary, the dose may be increased in 0.1-mL (1-mg) increments every few days.1


Patient is not a candidate for apomorphine therapy if clinically significant orthostatic hypotension occurs in response to initial 0.2-mL (2-mg) test dose.1


For patients who tolerate, but do not respond to the initial 0.2-mL (2-mg) test dose, administer a second test dose of 0.4 mL (4 mg) at the next observed “off” period, no sooner than 2 hours after the initial test dose.1 If the 0.4-mL (4-mg) dose is effective and tolerated, a 0.3-mL (3-mg) dose may be used on an as-needed, outpatient basis.1 If necessary, the dose may be increased in 0.1-mL (1-mg) increments every few days.1


For patients who respond, but do not tolerate the 0.4-mL (4-mg) test dose, administer a third test dose of 0.3 mL (3 mg) at the next observed “off” period, but no sooner than 2 hours after the 0.4-mL (4-mg) test dose.1 If the 0.3-mL (3-mg) dose is effective and tolerated, a 0.2-mL (2-mg) dose may be used on an as-needed, outpatient basis.1 If the 0.2-mL (2-mg) dose is tolerated, the dose may be increased, if needed, to 0.3 mL (3 mg) after a few days.1 The dose should not usually be increased to 0.4 mL (4 mg) on an outpatient basis in these patients.1


In clinical studies, most patients responded to doses of 0.3–0.6 mL (3–6 mg); average frequency of dosing was 3 times daily.1


If therapy has been interrupted for >1 week, reinitiate at a dose of 0.2 mL (2 mg) and gradually titrate to effect.1


Prescribing Limits


Adults


Hypomobility Episodes Associated with Parkinson's Disease

Sub-Q

No more than one dose of apomorphine should be administered for treatment of a single “off” episode.1 Safety and efficacy of a second dose during the same hypomobility episode in patients not responding to the initial dose have not been established.1


Doses >0.6 mL (6 mg) not associated with additional therapeutic effect and are not recommended.1


Limited experience with >5 doses per day or daily dosages >2 mL (20 mg).1


Special Populations


Hepatic Impairment


No special recommendations for patients with hepatic impairment.1 (See Hepatic Impairment under Cautions.)


Renal Impairment


In patients with mild or moderate renal impairment, initial test dose and subsequent starting dose is 0.1 mg (1 mg).1


Cautions for Apomorphine Hydrochloride


Contraindications



  • Concomitant use with selective 5-HT3 receptor antagonists.1 (See Specific Drugs under Interactions.)




  • Known hypersensitivity to apomorphine hydrochloride or any ingredient in the formulation (e.g., sodium metabisulfite).1



Warnings/Precautions


Warnings


Administration

Thrombus formation and pulmonary embolism reported following IV administration.1 14 Do not administer IV.1


Nausea and Vomiting

Severe nausea and vomiting expected; concomitant use of an antiemetic recommended.1 Trimethobenzamide was used in clinical studies; other antiemetics are contraindicated (i.e., 5-HT3 receptor antagonists) or not recommended (i.e., dopamine-receptor antagonists).1 (See General under Dosage and Administration and Specific Drugs under Interactions.)


Symptomatic Hypotension

Risk of orthostatic hypotension, hypotension, and/or syncope.1


Whether hypotension contributes to other adverse events (e.g., falls) unknown.1


Prolongation of QT Interval

Possible prolonged QT interval.1 Doses of ≤6 mg are associated with minimal increases in QTc interval.1


Use with caution in patients with congenital or known QT interval prolongation, in those with clinically important bradycardia, in those with uncorrected electrolyte disorders (e.g., hypokalemia, hypomagnesemia), and in those receiving drugs known to prolong the QTc interval.1


Nervous System and Muscular Effects

Risk of falls; may be due to postural and autonomic instability associated with Parkinson’s disease.1 Risk may be increased due to effect of apomorphine on BP and mobility.1


Symptom complex resembling neuroleptic malignant syndrome reported in association with abrupt withdrawal, dosage lowering, or changes in antiparkinsonian therapy.1


Hallucinations

Potential for hallucinations.1


Sudden Sleep Episodes

Falling asleep while engaged in activities of daily living has been reported in patients receiving apomorphine.1 While somnolence occurs frequently in patients receiving apomorphine, these patients perceived no warning signs and believed they were alert immediately prior to the event.1 Many experts believe that falling asleep while engaged in activities of daily living always occurs in a setting of preexisting somnolence, although patients may not give such a history.1


Continually reassess patients for drowsiness or sleepiness.1 Patients may not acknowledge drowsiness or sleepiness until directly questioned about such adverse effects during specific activities.1 Ask patients about any factors that may increase the risk of somnolence (e.g., concomitant sedating drugs, the presence of sleep disorders).1


Apomorphine generally should be discontinued if a patient develops clinically important daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., conversations, eating).1 If the drug is continued, the patients should be advised not to drive and to avoid other potentially dangerous activities.1 Insufficient information to establish whether dosage reduction will eliminate episodes of falling asleep while engaged in activities of daily living.1


Cardiovascular Effects

Risk of angina, MI, cardiac arrest, and/or sudden death.1 Angina and MI occurred in some patients within 2 hours of apomorphine dosing; cardiac arrest and sudden death occurred at times unrelated to dosing.1


May exacerbate coronary and cerebral ischemia due to effects of apomorphine on BP.1 Use with caution in patients with cardiovascular and cerebrovascular disease.1


If signs and symptoms of coronary or cerebral ischemia occur, reevaluate continued use of the drug.1


Injection Site Reactions

Injection site reactions (bruising, granuloma, pruritus) reported.1


Abuse and Misuse Potential

Escalation of apomorphine dose beyond the prescribed frequency reported in patients trying to avoid all symptoms of an “off” episode.1 Hypersexuality and increased erections can occur due to abuse of apomorphine.1 11


Monitor patients for excessive use (e.g., use out of proportion to motor signs).1


Sensitivity Reactions


Sulfite Sensitivity

The commercially available apomorphine hydrochloride injection contains sodium metabisulfite, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.1


General Precautions


Dyskinesia

May cause or exacerbate dyskinesias.1


Cardiorespiratory Fibrosis and Fibrotic Complications

Retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, and cardiac valvulopathy reported in patients receiving ergot-derivative dopamine receptor agonists; presumably related to the ergoline structure of these agents.1 Possible that nonergot-derived drugs that increase dopaminergic activity (e.g., apomorphine) may induce similar changes.1


Priapism

Possible prolonged painful erections.1


Ocular Effects

Retinal degeneration reported in albino rats given dopamine agonists for prolonged periods (usually 2-year carcinogenicity studies); similar changes not observed in albino mice, rats, or monkeys.1 Clinical importance in humans not established; however, effect cannot be disregarded because the presumed mechanism of action may apply to all vertebrates.1


Specific Populations


Pregnancy

Category C.1


Lactation

Not known whether apomorphine is distributed into milk.1 Discontinue nursing or the drug.1


Pediatric Use

Safety and efficacy for hypermobility episodes not established.1


Geriatric Use

Increased incidence of confusion, hallucinations, serious adverse events (life-threatening events or events resulting in hospitalization and/or increased disability), falls, cardiovascular events, respiratory disorders, and GI events in geriatric individuals compared with younger adults.1


Hepatic Impairment

Systemic exposure increased in patients with mild to moderate hepatic impairment; use with caution.1 Not studied in patients with severe hepatic impairment.1 (See Special Populations under Pharmacokinetics.)


Renal Impairment

Dosage adjustment necessary in patients with mild to moderate renal impairment.1 Not studied in patients with severe renal impairment or those undergoing dialysis.1 13 (See Renal Impairment under Dosage and Administration and Special Populations under Pharmacokinetics.)


Common Adverse Effects


Yawning, dyskinesias, nausea and/or vomiting, somnolence, dizziness, rhinorrhea, hallucinations, edema, chest pain, increased sweating, flushing, and pallor.1


Interactions for Apomorphine Hydrochloride


Drugs That Prolong QT Interval


Potential pharmacologic interaction (additive effect on QT interval prolongation).1 (See Prolongation of QT Interval under Cautions.)


Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes


Pharmacokinetic interaction unlikely.1


Specific Drugs
























Drug



Interaction



Comments



Antihypertensive agents and vasodilators



Potential pharmacologic interaction (additive hypotensive effects)1


Concomitant use associated with increased incidence of hypotension, MI, pneumonia, serious falls, bone and joint injuries1



Caution1



Catecho-O-methyltransferase (COMT) inhibitors



Pharmacokinetic interaction unlikely1 7



CNS depressants



Alcohol: Potential pharmacologic interaction (additive sedative and hypotensive effects)1


CNS depressants: Potential pharmacologic interaction (additive sedative effects)1



5-HT3 receptor antagonists (dolasetron, granisetron, ondansetron, palonosetron)



Potential pharmacologic interaction (profound hypotension and loss of consciousness)1



Concomitant use contraindicated1



Dopamine-receptor antagonists (e.g., phenothiazines, butyrophenones, thioxanthenes, metoclopramide)



Potential pharmacologic interaction (reduced efficacy of apomorphine)1



Phenothiazines, butyrophenones, thioxanthenes: Weigh benefits and risks of therapy with a dopamine agonist in patients receiving one of these dopamine-receptor antagonists for the treatment of major psychosis1



Levodopa/carbidopa



Potential pharmacologic interaction (additive neurologic effect; used to therapeutic effect)1


Pharmacokinetic interaction unlikely1


Apomorphine Hydrochloride Pharmacokinetics


Absorption


Bioavailability


Bioavailability following sub-Q administration is 100%.1 Peak plasma concentrations achieved in 10–60 minutes.1


Onset


Following sub-Q administration, therapeutic response usually achieved in 10–20 minutes.1 2 5 8 12


Duration


Approximately 60 minutes.1 2 5 8 12


Special Populations


In individuals with moderate hepatic impairment receiving a single sub-Q dose of apomorphine, peak plasma concentrations and AUC were increased 25 and 10%, respectively, compared with healthy individuals.1


In patients with moderate renal impairment receiving a single sub-Q dose of apomorphine, peak plasma concentrations and AUC were increased 50 and 16%, respectively, compared with healthy individuals.1 Time to peak plasma concentrations was not affected by renal status.1


Distribution


Extent


Maximum cerebrospinal fluid concentrations are <10% of peak plasma concentrations.1


Elimination


Metabolism


Routes of metabolism not known.1 Potential metabolic routes include sulfation, N–demethylation, glucuronidation, and oxidation.1


Half-life


40 minutes.1


Special Populations


Half-life not affected by renal status.1


Stability


Storage


Parenteral


Injection

25°C (may be exposed to 15–30°C).1


ActionsActions



  • Exhibits a higher affinity for dopamine D4 receptors in vitro than for dopamine D2, D3, or D5 receptors.1




  • Appears to act by stimulating postsynaptic dopamine D2 receptors in the caudate-putamen.1



Advice to Patients



  • Importance of taking apomorphine only as prescribed.1




  • Importance of instructing patient and/or caregiver regarding proper dosage and administration of apomorphine, including detailed instruction in the use of the dosing pen, in patients whose clinician has determined that the drug can safely and effectively be self-administered in the patient’s home by the patient, family member, or other responsible individual.1




  • Advise that hallucinations, hypotension, and other adverse effects (e.g., injection site reactions) may occur.1




  • Risk of orthostatic hypotension with or without dizziness, nausea, syncope, or sweating.1 Advise not to rise rapidly after prolonged sitting or lying down, especially during the first few weeks of therapy.1




  • Risk of somnolence and the possibility of falling asleep during activities of daily living; avoid driving or operating machinery until effects on the individual are known.1




  • Importance of informing clinicians if increased somnolence or new episodes of falling asleep during activities of daily living (e.g., watching television, riding in a car as a passenger) occur at any time during apomorphine therapy.1 Patients should not drive or participate in potentially dangerous activities until their clinician has been notified.1




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription (especially selective 5-HT3 receptor antagonists) and OTC drugs, as well as any concomitant illnesses.1




  • Importance of informing patients of other important precautionary information.1 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.













Apomorphine Hydrochloride (Hemihydrate)

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Parenteral



Injection, for sub-Q use only



10 mg/mL



Apokyn (with sodium metabisulfite; benzyl alcohol 0.5% in cartridges)



Mylan



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References



1. Mylan Bertek Pharmaceuticals Inc. Apokyn (apomorphine hydrochloride) injection prescribing information. Research Triangle Park, NC; 2004 Apr.



2. Stacy M. Apomorphine: North American clinical experience. Neurology. 2004; 62 (Suppl 4):S18-21. [IDIS 516185] [PubMed 15037667]



3. Dewey RB Jr. Management of motor complications in Parkinson's disease. Neurology. 2004; 62 (Suppl 4):S3-7. [IDIS 516182] [PubMed 15037664]



4. Anon. FDA approves Apokyn for the acute treatment of episodes of immobility in Parkinson’s patients. FDA Talk Paper. Rockville, MD: Food and Drug Administration; 2004 Apr 21.



5. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001; 58:1385-92. [IDIS 518541] [PubMed 11559309]



6. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97 414). Rockville, MD. From FDA website (). Accessed 2004 Aug 16.



7. Zijlmans JCM, Debilly B, Rascol O et. al. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Mov Disord. 2004; 19:1006-11. [PubMed 15372589]



8. Sherry JH, Guyton PJ, Van Lunen B, Bottini PB. Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease. Neurology. 2003; 60 (Suppl 1): A81.



9. Hughes AJ, Bishop S, Kleedorfer B et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 1993; 8:165-70. [PubMed 8474483]



10. Food and Drug Administration. Sulfiting agents; labeling in drugs for human use: warning statement. [Docket No. 84N-0113] Fed Regist. 1985; 50:47558-63.



11. Anon. Apomorphine (Apokyn) for advanced Parkinson's disease. Med Lett Drugs Ther. 2005; 47:7-8.



12. Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology. 2004; 62(Suppl 4):S12-7. [IDIS 516184] [PubMed 15037666]



13. Mylan Bertek Pharmaceuticals Inc. Apokyn (apomorphine hydrochloride) monograph. Research Triangle Park, NC; 2004 May 26.



14. Koller W, Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology. 2004; 62(Suppl 4):S22-6. [IDIS 516186] [PubMed 15037668]



15. AHFS Drug Information 1990. McEvoy, GK, ed. Apomorphine hydrochloride. Bethesda, MD: American Society of Health-System Pharmacists; 1990:1652-3.



16. Mylan Bertek Pharmaceuticals, Overland Park, KS: Personal communication.



More Apomorphine Hydrochloride resources


  • Apomorphine Hydrochloride Side Effects (in more detail)
  • Apomorphine Hydrochloride Use in Pregnancy & Breastfeeding
  • Apomorphine Hydrochloride Drug Interactions
  • Apomorphine Hydrochloride Support Group
  • 4 Reviews for Apomorphine Hydrochloride - Add your own review/rating


  • Apokyn Prescribing Information (FDA)

  • Apokyn Advanced Consumer (Micromedex) - Includes Dosage Information

  • Apokyn MedFacts Consumer Leaflet (Wolters Kluwer)

  • Apokyn Consumer Overview



Compare Apomorphine Hydrochloride with other medications


  • Parkinson's Disease
  • Tardive Dyskinesia

Saturday, 16 June 2012

Miscellaneous uncategorized agents


A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

See also

Medical conditions associated with miscellaneous uncategorized agents:

  • Acne
  • Acute Nonlymphocytic Leukemia
  • Amyotrophic Lateral Sclerosis
  • Barium Meal Transit
  • Bleeding Disorder
  • Cardiomyopathy Prophylaxis
  • Chronic Myelogenous Leukemia
  • Diagnosis and Investigation
  • Dupuytren's contracture
  • Extravasation
  • Gallbladder Contraction
  • Granuloma Annulare
  • Hyperammonemia
  • Hypercalcemia of Malignancy
  • Hyperkalemia
  • Hypodermoclysis
  • Melanoma, Metastatic
  • Mucositis
  • Obsessive Compulsive Disorder
  • Pancreatic Secretion
  • Penicillin Sensitization Testing
  • Pityriasis rubra pilaris
  • Porphyria
  • Rosacea
  • Secondary Hyperparathyroidism
  • Subcutaneous Urography
  • Thrombocythemia
  • Urea Cycle Disorders

Drug List:

Thursday, 14 June 2012

Calci Mix


Generic Name: calcium carbonate (KAL see um KAR boe nate)

Brand Names: Alka-Mints, Cal-Gest, Calcarb, Calci Mix, Calci-Chew, Calci-Mix, Calcium Concentrate, Calcium Liquid Softgel, Calcium Oyster Shell, Caltrate, Chooz, Extra Strength Mylanta Calci Tabs, Icar Prenatal Chewable Calcium, Maalox Antacid Barrier, Maalox Childrens', Maalox Quick Dissolve, Maalox Quick Dissolve Maximum Strength, Maalox Regular Strength, Mylanta Child, Nephro Calci, Os-Cal 500, Oysco 500, Oyst Cal 500, Oyster Cal, Oyster Calcium, Oyster Shell, Pepto Children's, Rolaids Sodium Free, Rolaids Soft Chew, Titralac, Tums, Tums 500, Tums E-X, Tums Kids, Tums QuikPak, Tums Ultra


What is Calci-Mix (calcium carbonate)?

Calcium is a mineral that is found naturally in foods. Calcium is necessary for many normal functions of the body, especially bone formation and maintenance. Calcium can also bind to other minerals (such as phosphate) and aid in their removal from the body.


Calcium carbonate is used to prevent and to treat calcium deficiencies.


Calcium carbonate may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Calci-Mix (calcium carbonate)?


Do not take calcium carbonate or antacids that contain calcium without first asking your doctor if you also take other medicines. Calcium can make it harder for your body to absorb certain medicines. Calcium carbonate works best if you take it with food.

What should I discuss with my healthcare provider before taking Calci-Mix (calcium carbonate)?


To make sure you can safely take calcium carbonate, tell your doctor if you have any of these other conditions:



  • a history of kidney stones; or




  • a parathyroid gland disorder.




Talk to your doctor before taking calcium carbonate if you are pregnant. Talk to your doctor before taking calcium carbonate if you are breast-feeding a baby.

How should I take Calci-Mix (calcium carbonate)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.


Calcium carbonate works best if you take it with food. Swallow the calcium carbonate tablet or capsule with a full glass of water.

The chewable tablet should be chewed before you swallow it.


Use the calcium carbonate powder as directed. Allow the powder to dissolve completely, then consume the mixture.


Shake the oral suspension (liquid) well just before you measure a dose. Measure the liquid with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one. Store at room temperature away from moisture and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include nausea, vomiting, decreased appetite, constipation, confusion, delirium, stupor, and coma.


What should I avoid while taking Calci-Mix (calcium carbonate)?


Follow your healthcare provider's instructions about any restrictions on food, beverages, or activity.


Calci-Mix (calcium carbonate) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:



  • nausea or vomiting;




  • decreased appetite;




  • constipation;




  • dry mouth or increased thirst; or




  • urinating more than usual.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs can affect Calci-Mix (calcium carbonate)?


Calcium carbonate can make it harder for your body to absorb other medications you take by mouth. Tell your doctor if you are taking:



  • digoxin (Lanoxin, Lanoxicaps);




  • antacids or other calcium supplements;




  • calcitriol (Rocaltrol) or vitamin D supplements; or




  • doxycycline (Adoxa, Doryx, Oracea, Vibramycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap).



This list is not complete and other drugs may interact with calcium carbonate. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Calci-Mix resources


  • Calci-Mix Side Effects (in more detail)
  • Calci-Mix Use in Pregnancy & Breastfeeding
  • Calci-Mix Drug Interactions
  • Calci-Mix Support Group
  • 0 Reviews for Calci-Mix - Add your own review/rating


Compare Calci-Mix with other medications


  • Duodenal Ulcer
  • Erosive Esophagitis
  • GERD
  • Hypocalcemia
  • Indigestion
  • Osteopenia
  • Osteoporosis
  • Stomach Ulcer


Where can I get more information?


  • Your doctor or pharmacist can provide more information about calcium carbonate.

See also: Calci-Mix side effects (in more detail)